Clinical trial · Observational
Prospective Evaluation of Efficacy and Safety of Fondaparinux in Surgical Cancer Patients, Risk Factors for Thromboembolism
Prospective Evaluation of Efficacy and Safety of Fondaparinux in Surgical Cancer Patients, Identification of the Most Relevant Risk Factors for Thromboembolism
NCT04246073CI-TRIAL-00046330unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Non interventional multi-centric study that will aim in evaluating the efficacy and safety of Fondaparinux in surgical cancer patients, identifying in parallel the most relevant and critical risk factors for Thromboembolism.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Cancer Diagnosis | — | UNRESOLVED | — |
| Thromboembolism | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (4)
- measure
- Number of incidents
- timeFrame
- One Year
- description
- Observed number of incidents per cancer type
- measure
- Number of bleeding episodes
- timeFrame
- One Year
- description
- The incidence of bleeding episodes by type of cancer
- measure
- Comparison of results/incidents among groups
- timeFrame
- One Year
- description
- Results of treatment in subgroups of patients (for example patients with newly diagnosed cancer or potential cancer or relapse / metastasis of cancer that has been treated before and diagnosed ≥ 1 year)
- measure
- Evaluation
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Upcoming surgery for newly diagnosed or potential cancer or relapse / metastasis of cancer that has been treated and diagnosed ≥ 1 year Exclusion Criteria: * Recent (\<6 months) episode of venous thromboembolic disease (Deep vein thrombosis and / or pulmonary embolism and / or thrombosis in a rare location such as visceral or cerebral venous thrombosis) * Pregnancy or pregnancy * Patients on long-term anticoagulation for any reason (MKH, HMB or ABK, DOACs) at prophylactic or therapeutic dose, prior to enrollment in the study. * Active haemorrhage, diagnosed hemorrhagic disorder, thrombocytopenia * Ulcers or vasodilatations of the gastrointestinal tract * Hemorrhagic stroke or surgery in the brain, spine or eye of the last trimester * Bacterial endocarditis or other contraindication to the use of anticoagulant treatment * Creatinine clearance \<20mL / min * Thrombolytic treatment or administration of dextran in the 2 days preceding administration of fondaparinux
References
Publications (0)
Data not yet available
No reference posted for this study.